drugset / Trial / NCT05976360
A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1, single subcutaneous dose study to evaluate safety and pharmacokinetics of 2 different dupilumab drug product in healthy volunteers. The duration per participant is up to 11 weeks.
Timeline
- Start
- 2014-11-02
- Primary completion
- 2015-01-17
- Completion
- 2015-01-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dupilumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.